Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioSpecifics Technologies Corp. (NASDAQ: BSTC).

Full DD Report for BSTC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BSTC)

BioSpecifics Tech misses by $0.05, misses on revenue
BioSpecifics Tech (NASDAQ: BSTC ): Q1 EPS of $0.54 misses by $0.05 . More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 08:05
BioSpecifics Technologies Corp. Reports First Quarter 2018 Financial Results
LYNBROOK, N.Y. , May 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and...
Source: PR Newswire
Date: May, 09 2018 08:01
New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd. (NASDAQ:IMOS), POSC...
Source: GlobeNewswire
Date: April, 11 2018 08:20
Blog Exposure - Vericel Announced Publication of Results from Phase-3 SUMMIT Extension Study
Stock Monitor: BioSpecifics Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Vericel Corp. (NASDAQ: VCEL ). If you want access to this report all you need to do is sign up now by clicking ...
Source: ACCESSWIRE IA
Date: March, 27 2018 07:20
New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNB Financial Corporation (NASDAQ:CCNE), Akebia Therapeutics, Inc. (NASD...
Source: GlobeNewswire
Date: March, 16 2018 08:30
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results
LYNBROOK, N.Y. , March 14, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. ...
Source: PR Newswire
Date: March, 14 2018 08:01
BioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation
LYNBROOK, N.Y. , March 12, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX ®  in the U.S...
Source: PR Newswire
Date: March, 12 2018 16:30
BioSpecifics Technologies Corp. to Present at the NobleCon14 Conference
LYNBROOK, N.Y. , Jan. 22, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S...
Source: PR Newswire
Date: January, 22 2018 08:00
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market....
Source: SeekingAlpha
Date: January, 03 2018 01:25
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portola’s ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu...
Source: SeekingAlpha
Date: December, 28 2017 01:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-2543.0043.0043.234142.2815,498
2018-05-2442.8342.8143.02542.49995,497
2018-05-2342.7042.8043.289942.515913,741
2018-05-2243.4942.7843.4942.6027,748
2018-05-2143.6043.4243.6342.340117,190

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-252,8629,42030.3822Cover
2018-05-249031,51059.8013Short
2018-05-231,0017,26013.7879Cover
2018-05-227,9299,30585.2123Short
2018-05-213,5035,86759.7068Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BSTC.


About BioSpecifics Technologies Corp. (NASDAQ: BSTC)

Logo for BioSpecifics Technologies Corp. (NASDAQ: BSTC)

Not available

 

Contact Information

 

 

Current Management

  • Tom Wegman / President, Principal Executive Officer, Principal Fin. Officer
  • Tom Wegman /

Current Share Structure

  • Market Cap: $307,047,287 - 05/11/2018
  • Issue and Outstanding: 7,199,233 - 03/13/2018

 


Recent Filings from (NASDAQ: BSTC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 16 2018

 

 


Daily Technical Chart for (NASDAQ: BSTC)

Daily Technical Chart for (NASDAQ: BSTC)


Stay tuned for daily updates and more on (NASDAQ: BSTC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BSTC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BSTC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BSTC and does not buy, sell, or trade any shares of BSTC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/